Zoetis [ZTS] vs United Therapeutics [UTHR] Detailed Stock Comparison

Zoetis

NYSE
Loading...

United Therapeutics

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Zoetis wins in 5 metrics, United Therapeutics wins in 14 metrics, with 0 ties. United Therapeutics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricZoetisUnited TherapeuticsBetter
P/E Ratio (TTM)24.6816.92United Therapeutics
Price-to-Book Ratio12.772.68United Therapeutics
Debt-to-Equity Ratio137.010.00United Therapeutics
PEG Ratio1.411.77Zoetis
EV/EBITDA17.3810.11United Therapeutics
Profit Margin (TTM)27.83%40.36%United Therapeutics
Operating Margin (TTM)40.20%45.64%United Therapeutics
EBITDA Margin (TTM)40.20%45.64%United Therapeutics
Return on Equity52.77%19.30%Zoetis
Return on Assets (TTM)15.37%12.96%Zoetis
Free Cash Flow (TTM)$2.30B$1.08BZoetis
Dividend Yield1.11%N/AN/A
1-Year Return-26.34%24.59%United Therapeutics
Price-to-Sales Ratio (TTM)6.766.37United Therapeutics
Enterprise Value$68.57B$16.14BZoetis
EV/Revenue Ratio7.315.24United Therapeutics
Gross Profit Margin (TTM)73.62%89.03%United Therapeutics
Revenue per Share (TTM)$21$69United Therapeutics
Earnings per Share (Diluted)$5.80$25.12United Therapeutics
Beta (Stock Volatility)0.890.62United Therapeutics
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Zoetis vs United Therapeutics Stock Performance Analysis

Loading Price Chart...

Zoetis
United Therapeutics
Zoetis Stock Overview | United Therapeutics Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Zoetis1.51%-1.63%-7.29%-7.89%-11.87%-11.75%
United Therapeutics1.20%4.24%9.54%50.21%42.01%23.10%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Zoetis-26.34%-3.23%-12.26%233.57%362.75%362.75%
United Therapeutics24.59%114.46%326.34%258.80%694.13%1,312.23%

News Based Sentiment: Zoetis vs United Therapeutics

Zoetis

News based Sentiment: MIXED

The month featured both positive developments – the CVMP opinion for Portela® and generally positive analyst estimates – alongside negative signals like stock decline, technical warnings, and mixed institutional activity. This creates a balanced, rather than decisively positive or negative, investment narrative.

View Zoetis News Sentiment Analysis

United Therapeutics

News based Sentiment: MIXED

September was a pivotal month for United Therapeutics, marked by the highly positive TETON-2 trial results for Tyvaso in IPF, which drove significant stock gains and analyst upgrades. However, substantial insider selling and ongoing legal battles with Liquidia create a mixed investment picture, requiring careful monitoring of both the opportunities and risks.

View United Therapeutics News Sentiment Analysis

Performance & Financial Health Analysis: Zoetis vs United Therapeutics

MetricZTSUTHR
Market Information
Market Cap i$63.73B$19.33B
Market Cap CategoryN/ALarge cap
10 Day Avg. Volume i2,724,607924,001
90 Day Avg. Volume i2,517,512904,024
Last Close$167.10$443.44
52 Week Range$139.70 - $200.33$266.98 - $444.57
% from 52W High-16.59%-0.25%
All-Time High$249.27 (Dec 27, 2021)$444.57 (Oct 02, 2025)
% from All-Time High-32.96%-0.25%
Growth Metrics
Quarterly Revenue Growth0.04%0.12%
Quarterly Earnings Growth0.15%0.11%
Financial Health
Profit Margin (TTM) i0.28%0.40%
Operating Margin (TTM) i0.40%0.46%
Return on Equity (TTM) i0.53%0.19%
Debt to Equity (MRQ) i137.010.00
Cash & Liquidity
Book Value per Share (MRQ)$11.21$158.65
Cash per Share (MRQ)$3.28$67.41
Operating Cash Flow (TTM) i$2.93B$1.37B
Levered Free Cash Flow (TTM) i$2.29B$811.05M
Dividends
Last 12-Month Dividend Yield i1.11%N/A
Last 12-Month Dividend i$1.86N/A

Valuation & Enterprise Metrics Analysis: Zoetis vs United Therapeutics

MetricZTSUTHR
Price Ratios
P/E Ratio (TTM) i24.6816.92
Forward P/E i22.5715.25
PEG Ratio i1.411.77
Price to Sales (TTM) i6.766.37
Price to Book (MRQ) i12.772.68
Market Capitalization
Market Capitalization i$63.73B$19.33B
Enterprise Value i$68.57B$16.14B
Enterprise Value Metrics
Enterprise to Revenue i7.315.24
Enterprise to EBITDA i17.3810.11
Risk & Other Metrics
Beta i0.890.62
Book Value per Share (MRQ) i$11.21$158.65

Financial Statements Comparison: Zoetis vs United Therapeutics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)ZTSUTHR
Revenue/Sales i$2.22B$794.40M
Cost of Goods Sold i$622.00M$92.50M
Gross Profit i$1.60B$701.90M
Research & Development i$157.00M$149.00M
Operating Income (EBIT) i$846.00M$382.80M
EBITDA i$991.00M$449.40M
Pre-Tax Income i$810.00M$423.50M
Income Tax i$179.00M$101.30M
Net Income (Profit) i$631.00M$322.20M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)ZTSUTHR
Cash & Equivalents i$1.72B$1.90B
Total Current Assets i$5.88B$3.94B
Total Current Liabilities i$3.39B$721.50M
Long-Term Debt i$5.40BN/A
Total Shareholders Equity i$4.66B$6.81B
Retained Earnings i$12.38B$7.54B
Property, Plant & Equipment i$6.36B$0

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)ZTSUTHR
Operating Cash Flow i$567.00M$463.80M
Capital Expenditures iN/A$-74.90M
Free Cash Flow i$438.00M$386.30M
Debt Repayment iN/A$-100.00M
Common Stock Repurchase i$-443.00M$0

Short Interest & Institutional Ownership Analysis

MetricZTSUTHR
Shares Short i7.76M2.78M
Short Ratio i2.403.12
Short % of Float i0.02%0.08%
Average Daily Volume (10 Day) i2,724,607924,001
Average Daily Volume (90 Day) i2,517,512904,024
Shares Outstanding i448.47M44.83M
Float Shares i442.31M42.01M
% Held by Insiders i0.00%0.02%
% Held by Institutions i0.99%1.00%

Dividend Analysis & Yield Comparison: Zoetis vs United Therapeutics

MetricZTSUTHR
Last 12-Month Dividend i$1.86N/A
Last 12-Month Dividend Yield i1.11%N/A
3-Year Avg Annual Dividend i$1.63N/A
3-Year Avg Dividend Yield i0.24%N/A
3-Year Total Dividends i$4.90N/A
Ex-Dividend DateApr 21, 2025N/A